Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKesson
Express Scripts
Johnson and Johnson
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

HUMULIN 70/30 Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Humulin 70/30, and what generic alternatives are available?

Humulin 70/30 is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

Drug patent expirations by year for HUMULIN 70/30
Drug Sales Revenue Trends for HUMULIN 70/30

See drug sales revenues for HUMULIN 70/30

Recent Clinical Trials for HUMULIN 70/30

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Juvenile Diabetes Research FoundationPhase 2
HealthPartners InstitutePhase 2
International Diabetes Center at Park NicolletPhase 2

See all HUMULIN 70/30 clinical trials

Synonyms for HUMULIN 70/30
1021924-27-5
1038820-20-0
1104460-98-1
11061-68-0
1146625-72-0
1171191-96-0
1171210-94-8
1171228-96-8
1171244-30-6
1245604-13-0
1Y17CTI5SR
Actrapid
Actrapid HM
Biohulin
H-Tronin
Human Protaphane
IN 105
Incelligent AF
Incelligent SG
Insugen
Insulin human (biosynthesis)
Insulin human [USAN:USP:INN:BAN]
Insulin U-500
Insulin, Regular, Human
Insulin(human)
Insulina humana
Insuline humaine
Insulinum humanum
Insuman Rapid
Isuhuman
Jusuline
NN 1953
Novolin
Oral-lyn
ORMD 0801
Regular human insulin
Umulin
Umulin Rapide
UNII-1Y17CTI5SR
Velosulin HM
Velosuline HM
Viaject

US Patents and Regulatory Information for HUMULIN 70/30

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMULIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717-001 Apr 25, 1989 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
Lilly HUMULIN 70/30 PEN insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717-002 Aug 6, 1998 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for HUMULIN 70/30

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0705275 SPC/GB00/027 United Kingdom   Start Trial PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
2498802 300883 Netherlands   Start Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
2209800 122014000114 Germany   Start Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
2498802 C201730022 Spain   Start Trial PRODUCT NAME: SULIQUA-INSULINA GLARGINA/ LIXISENATIDA; NATIONAL AUTHORISATION NUMBER: EU/1/16/1157; DATE OF AUTHORISATION: 20170111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1157; DATE OF FIRST AUTHORISATION IN EEA: 20170111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.